RECRUITING

Blood Flow Restriction Following Hip Arthroscopy

Talk to us

Conditions

Labral Tear, GlenoidFemoral Acetabular Impingement

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will be a prospective randomized, double-blinded, placebo-controlled trial of patients undergoing primary hip arthroscopy for FAIS and/or labral pathology. All patients who sign the consent form will be enrolled in the study and randomized to one of the two treatment arms. Follow-up will take place at 1-month, 3-months, 6-months, and 1-year.

Official Title

Postoperative Blood Flow Restriction Training Following Hip Arthroscopy: A Randomized Clinical Trial

Quick Facts

Study Start:2023-08-01
Study Completion:2026-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04113759

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 40 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Adult patients 18-40
  2. * English-speaking
  3. * Clinical and radiographic examination (MRI) consistent FAIS and/or labral pathology, and are schedule for primary hip arthroscopy
  4. * Written and informed consent for study participation
  1. * Patients younger than 18 or older than 40 years of age
  2. * Non-native English speaker
  3. * Revision surgery or prior history of ipsilateral hip or knee surgery
  4. * Inability to comply with the proposed follow-up clinic visits
  5. * Patients lacking decisional capacity
  6. * Patients with a history of deep vein thrombosis, pulmonary embolism, or known clotting disorder or hypercoagulable state
  7. * Pregnant or breast-feeding women. Pregnancy as determined by a positive pregnancy test prior to procedure. Females of childbearing potential must agree to use an acceptable birth control method during study participation.
  8. * Worker's compensation patients
  9. * Any clinically significant finding that would place the patient at health risk, impact the study, or affect the completion of the study
  10. * Any psychiatric illness that would prevent comprehension of the details and nature of the study and interfere with follow-up clinic visits

Contacts and Locations

Study Contact

Carla M. Edwards, PhD
CONTACT
312-563-5735
carla_edwards@rush.edu

Principal Investigator

Jorge Chahla, MD PhD
PRINCIPAL_INVESTIGATOR
Rush University Medical Center

Study Locations (Sites)

Rush University Medical Center
Chicago, Illinois, 60612
United States

Collaborators and Investigators

Sponsor: Rush University Medical Center

  • Jorge Chahla, MD PhD, PRINCIPAL_INVESTIGATOR, Rush University Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-08-01
Study Completion Date2026-01

Study Record Updates

Study Start Date2023-08-01
Study Completion Date2026-01

Terms related to this study

Additional Relevant MeSH Terms

  • Labral Tear, Glenoid
  • Femoral Acetabular Impingement